Sorafenib as an Inhibitor of RUVBL2
RUVBL1 and RUVBL2 are highly conserved ATPases that belong to the AAA+ (ATPases Associated with various cellular Activities) superfamily and are involved in various complexes and cellular processes, several of which are closely linked to oncogenesis. The proteins were implicated in DNA damage signal...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-04-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/10/4/605 |
| _version_ | 1827718684947251200 |
|---|---|
| author | Nardin Nano Francisca Ugwu Thiago V. Seraphim Tangzhi Li Gina Azer Methvin Isaac Michael Prakesch Leandro R. S. Barbosa Carlos H. I. Ramos Alessandro Datti Walid A. Houry |
| author_facet | Nardin Nano Francisca Ugwu Thiago V. Seraphim Tangzhi Li Gina Azer Methvin Isaac Michael Prakesch Leandro R. S. Barbosa Carlos H. I. Ramos Alessandro Datti Walid A. Houry |
| author_sort | Nardin Nano |
| collection | DOAJ |
| description | RUVBL1 and RUVBL2 are highly conserved ATPases that belong to the AAA+ (ATPases Associated with various cellular Activities) superfamily and are involved in various complexes and cellular processes, several of which are closely linked to oncogenesis. The proteins were implicated in DNA damage signaling and repair, chromatin remodeling, telomerase activity, and in modulating the transcriptional activities of proto-oncogenes such as c-Myc and β-catenin. Moreover, both proteins were found to be overexpressed in several different types of cancers such as breast, lung, kidney, bladder, and leukemia. Given their various roles and strong involvement in carcinogenesis, the RUVBL proteins are considered to be novel targets for the discovery and development of therapeutic cancer drugs. Here, we describe the identification of sorafenib as a novel inhibitor of the ATPase activity of human RUVBL2. Enzyme kinetics and surface plasmon resonance experiments revealed that sorafenib is a weak, mixed non-competitive inhibitor of the protein’s ATPase activity. Size exclusion chromatography and small angle X-ray scattering data indicated that the interaction of sorafenib with RUVBL2 does not cause a significant effect on the solution conformation of the protein; however, the data suggested that the effect of sorafenib on RUVBL2 activity is mediated by the insertion domain in the protein. Sorafenib also inhibited the ATPase activity of the RUVBL1/2 complex. Hence, we propose that sorafenib could be further optimized to be a potent inhibitor of the RUVBL proteins. |
| first_indexed | 2024-03-10T20:28:53Z |
| format | Article |
| id | doaj.art-40be1c99378d4d0fb94c547cbb4264ba |
| institution | Directory Open Access Journal |
| issn | 2218-273X |
| language | English |
| last_indexed | 2024-03-10T20:28:53Z |
| publishDate | 2020-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj.art-40be1c99378d4d0fb94c547cbb4264ba2023-11-19T21:32:25ZengMDPI AGBiomolecules2218-273X2020-04-0110460510.3390/biom10040605Sorafenib as an Inhibitor of RUVBL2Nardin Nano0Francisca Ugwu1Thiago V. Seraphim2Tangzhi Li3Gina Azer4Methvin Isaac5Michael Prakesch6Leandro R. S. Barbosa7Carlos H. I. Ramos8Alessandro Datti9Walid A. Houry10Department of Biochemistry, University of Toronto, Toronto, ON M5G 1M1, CanadaDepartment of Biochemistry, University of Toronto, Toronto, ON M5G 1M1, CanadaDepartment of Biochemistry, University of Toronto, Toronto, ON M5G 1M1, CanadaDepartment of Biochemistry, University of Toronto, Toronto, ON M5G 1M1, CanadaDepartment of Biochemistry, University of Toronto, Toronto, ON M5G 1M1, CanadaDrug Discovery Program, Ontario Institute for Cancer Research, Toronto, ON M5G 0A3, CanadaDrug Discovery Program, Ontario Institute for Cancer Research, Toronto, ON M5G 0A3, CanadaInstitute of Physics, University of São Paulo, São Paulo SP 05508-090, BrazilInstitute of Chemistry, University of Campinas UNICAMP, Campinas SP 13083-970, BrazilDepartment of Agriculture, Food, and Environmental Sciences, University of Perugia, 06121 Perugia, ItalyDepartment of Biochemistry, University of Toronto, Toronto, ON M5G 1M1, CanadaRUVBL1 and RUVBL2 are highly conserved ATPases that belong to the AAA+ (ATPases Associated with various cellular Activities) superfamily and are involved in various complexes and cellular processes, several of which are closely linked to oncogenesis. The proteins were implicated in DNA damage signaling and repair, chromatin remodeling, telomerase activity, and in modulating the transcriptional activities of proto-oncogenes such as c-Myc and β-catenin. Moreover, both proteins were found to be overexpressed in several different types of cancers such as breast, lung, kidney, bladder, and leukemia. Given their various roles and strong involvement in carcinogenesis, the RUVBL proteins are considered to be novel targets for the discovery and development of therapeutic cancer drugs. Here, we describe the identification of sorafenib as a novel inhibitor of the ATPase activity of human RUVBL2. Enzyme kinetics and surface plasmon resonance experiments revealed that sorafenib is a weak, mixed non-competitive inhibitor of the protein’s ATPase activity. Size exclusion chromatography and small angle X-ray scattering data indicated that the interaction of sorafenib with RUVBL2 does not cause a significant effect on the solution conformation of the protein; however, the data suggested that the effect of sorafenib on RUVBL2 activity is mediated by the insertion domain in the protein. Sorafenib also inhibited the ATPase activity of the RUVBL1/2 complex. Hence, we propose that sorafenib could be further optimized to be a potent inhibitor of the RUVBL proteins.https://www.mdpi.com/2218-273X/10/4/605RUVBL2RUVBL1SorafenibAAA+ proteinsInhibition |
| spellingShingle | Nardin Nano Francisca Ugwu Thiago V. Seraphim Tangzhi Li Gina Azer Methvin Isaac Michael Prakesch Leandro R. S. Barbosa Carlos H. I. Ramos Alessandro Datti Walid A. Houry Sorafenib as an Inhibitor of RUVBL2 Biomolecules RUVBL2 RUVBL1 Sorafenib AAA+ proteins Inhibition |
| title | Sorafenib as an Inhibitor of RUVBL2 |
| title_full | Sorafenib as an Inhibitor of RUVBL2 |
| title_fullStr | Sorafenib as an Inhibitor of RUVBL2 |
| title_full_unstemmed | Sorafenib as an Inhibitor of RUVBL2 |
| title_short | Sorafenib as an Inhibitor of RUVBL2 |
| title_sort | sorafenib as an inhibitor of ruvbl2 |
| topic | RUVBL2 RUVBL1 Sorafenib AAA+ proteins Inhibition |
| url | https://www.mdpi.com/2218-273X/10/4/605 |
| work_keys_str_mv | AT nardinnano sorafenibasaninhibitorofruvbl2 AT franciscaugwu sorafenibasaninhibitorofruvbl2 AT thiagovseraphim sorafenibasaninhibitorofruvbl2 AT tangzhili sorafenibasaninhibitorofruvbl2 AT ginaazer sorafenibasaninhibitorofruvbl2 AT methvinisaac sorafenibasaninhibitorofruvbl2 AT michaelprakesch sorafenibasaninhibitorofruvbl2 AT leandrorsbarbosa sorafenibasaninhibitorofruvbl2 AT carloshiramos sorafenibasaninhibitorofruvbl2 AT alessandrodatti sorafenibasaninhibitorofruvbl2 AT walidahoury sorafenibasaninhibitorofruvbl2 |